Linked Life Data

9549815

Source:http://linkedlifedata.com/resource/pubmed/id/9549815

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5-7
pubmed:dateCreated
1998-5-28
pubmed:abstractText
Assessment of health related quality of life has become an important endpoint in many cancer clinical trials. Because the participants of these trials often experience disease and treatment related morbidity and mortality, non-random missing assessments are inevitable. Examples are presented from several such trials that illustrate the impact of missing data on the analysis of QOL in these trials. The sensitivity of different analyses depends on the proportion of assessments that are missing and the strength of the association of the underlying reasons for missing data with disease and treatment related morbidity and mortality. In the setting of clinical trials of cancer therapy, the assumption that the data are missing completely at random (MCAR) and analyses of complete cases is usually unjustified. Further, the assumption of missing at random (MAR) may also be violated in many trials and models appropriate for non-ignorable missing data should be explored. Recommendations are presented to minimize missing data, to obtain useful documentation concerning the reasons for missing data and to perform sensitivity analyses.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0277-6715
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
667-77
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Why are missing quality of life data a problem in clinical trials of cancer therapy?
pubmed:affiliation
Center for Methodologic Research and Biometry, AMC Cancer Research Center, Denver, CO 80214, USA. fairclough@amc.org
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.